Showing results (251-260 of 379) with videos related to

Sort By:
Pageof 38
Diabetes, Obesity & Metabolism|June 22, 2017
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trialPer-Henrik Groop, Mark E Cooper, Vlado Perkovic, et al.
Annals of Internal Medicine|May 5, 2010
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney diseaseSuetonia C Palmer, Sankar D Navaneethan, Jonathan C Craig, et al.
Cardiovascular Research|April 7, 2021
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trialJie Yu, Jingwei Li, Phillip J Leaver, et al.
Diabetes Care|March 24, 2016
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ONMuh Geot Wong, Vlado Perkovic, John Chalmers, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 2, 2019
Varying Association of Extended Hours Dialysis with Quality of LifeBrendan Smyth, Oliver van den Broek-Best, Daqing Hong, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trialJeroen V Koomen, Jasper Stevens, George Bakris, et al.
Kidney International Reports|April 30, 2025
Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKDBernard Chan, Amanda Varghese, Sunil V Badve, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 1, 2016
The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled TrialMatthew A Roberts, Helen L Pilmore, Francesco L Ierino, et al.
Diabetes, Obesity & Metabolism|June 19, 2024
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trialKathryn Cardoza, Amy Kang, Brendan Smyth, et al.
Diabetology International|March 25, 2020
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trialNobuya Inagaki, Wenying Yang, Hirotaka Watada, et al.
Pageof 38